TERN vs. PGEN, URGN, NKTX, ATAI, RANI, NLTX, SBTX, AVIR, ORGO, and FBLG
Should you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Precigen (PGEN), UroGen Pharma (URGN), Nkarta (NKTX), Atai Life Sciences (ATAI), Rani Therapeutics (RANI), Neoleukin Therapeutics (NLTX), Silverback Therapeutics (SBTX), Atea Pharmaceuticals (AVIR), Organogenesis (ORGO), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical preparations" industry.
Terns Pharmaceuticals (NASDAQ:TERN) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.
Precigen received 390 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 67.03% of users gave Precigen an outperform vote while only 59.32% of users gave Terns Pharmaceuticals an outperform vote.
98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 17.4% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 41.7% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Terns Pharmaceuticals presently has a consensus target price of $14.94, suggesting a potential upside of 158.88%. Precigen has a consensus target price of $10.00, suggesting a potential upside of 638.01%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Terns Pharmaceuticals.
Terns Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -1,540.63%. Terns Pharmaceuticals' return on equity of -33.55% beat Precigen's return on equity.
Terns Pharmaceuticals has higher earnings, but lower revenue than Precigen. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
Terns Pharmaceuticals has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.
In the previous week, Terns Pharmaceuticals had 2 more articles in the media than Precigen. MarketBeat recorded 2 mentions for Terns Pharmaceuticals and 0 mentions for Precigen. Terns Pharmaceuticals' average media sentiment score of 0.00 equaled Precigen'saverage media sentiment score.
Summary
Terns Pharmaceuticals beats Precigen on 9 of the 17 factors compared between the two stocks.
Get Terns Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Terns Pharmaceuticals Competitors List
Related Companies and Tools
